| Literature DB >> 29566794 |
Chihiro Sato1, Nicolas R Barthélemy2, Kwasi G Mawuenyega2, Bruce W Patterson3, Brian A Gordon4, Jennifer Jockel-Balsarotti2, Melissa Sullivan2, Matthew J Crisp2, Tom Kasten2, Kristopher M Kirmess3, Nicholas M Kanaan5, Kevin E Yarasheski3, Alaina Baker-Nigh3, Tammie L S Benzinger4, Timothy M Miller6, Celeste M Karch7, Randall J Bateman8.
Abstract
We developed stable isotope labeling and mass spectrometry approaches to measure the kinetics of multiple isoforms and fragments of tau in the human central nervous system (CNS) and in human induced pluripotent stem cell (iPSC)-derived neurons. Newly synthesized tau is truncated and released from human neurons in 3 days. Although most tau proteins have similar turnover, 4R tau isoforms and phosphorylated forms of tau exhibit faster turnover rates, suggesting unique processing of these forms that may have independent biological activities. The half-life of tau in control human iPSC-derived neurons is 6.74 ± 0.45 days and in human CNS is 23 ± 6.4 days. In cognitively normal and Alzheimer's disease participants, the production rate of tau positively correlates with the amount of amyloid plaques, indicating a biological link between amyloid plaques and tau physiology.Entities:
Keywords: Alzheimer’s disease; PET; SILK; amyloid; human; induced pluripotent stem cell; isoform; phosphorylation; positron emission tomography; production rate; stable isotope labeling kinetics; tau
Mesh:
Substances:
Year: 2018 PMID: 29566794 PMCID: PMC6137722 DOI: 10.1016/j.neuron.2018.02.015
Source DB: PubMed Journal: Neuron ISSN: 0896-6273 Impact factor: 17.173